57338-24-6

Upstream product

• 42466-67-1 ethyl (ethoxymethylene)cyanoacetate 
• 100-01-6 4-nitro-aniline 
• 94-05-3 ethyl (ethoxymethylene)cyanoacetate 
• 94-05-3 2-cyano-3-ethoxyacrylic acid ethyl ester 

Downstream Products

• 214484-15-8 N-[4-[(3-bromophenyl)amino]-3-cyano-6-quinolinyl]-2-propenamide 
• 214485-09-3 4-[(3-chloro-4-fluorophenyl)amino]-6-nitro-quinoline-3-carbonitrile 
• 214485-08-2 6-Amino-4-[(3-chloro-4-fluorophenyl)amino]-quinoline-3-carbonitrile 
• 214484-09-0 4-[(3-bromophenyl)amino]-6-nitro-quinoline-3-carbonitrile 
• 214484-11-4 6-amino-4-[(3-bromophenyl)-amino]-3-quinolinecarbonitrile 
• 214470-37-8 4-chloro-6-nitro-3-quinolinecarbonitrile 
• 2305-65-9 4-hydroxy-6-nitroquinoline-3-carbonitrile 

Relevant academic research and scientific papers

NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND APPLICATION

A nitrogenous heterocyclic compound, a preparation method, an intermediate, a composition, and an application. The present invention provides a nitrogenous heterocyclic compound as represented by formula I, pharmaceutically acceptable salts thereof, enantiomers thereof, diastereoisomers thereof, tautomers thereof, solvates thereof, metabolites thereof, or prodrugs thereof. The compound has high inhibitory activity against ErbB2 tyrosine kinase, has good inhibitory activity against human breast cancer cells BT-474, human gastric cancer cells NCI-N87 and the like with high expression of ErbB2, and in addition has relatively weak inhibitory activity against EGFR kinase, that is, the compound is an EGFR/ErbB2 double target inhibitor that attenuates EGFR kinase inhibitory activity or a small-molecule inhibitor having selectivity for an ErbB2 target. (I)

SUBSTITUTED QUINOLINES AS BRUTON'S TYROSINE KINASES INHIBITORS

The present invention is directed to novel quinolines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are useful f

Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epi

A series of of 6,7-disubstituted-4-anilinoquinoline-3-carbonitrile derivatives that function as irreversible inhibitors of EGFR and HER-2 kinases have been prepared. These inhibitors have, at the 6-position, butynamide, crotonamide, and methacrylamide Mic